Abbott returns U.S. marketing rights to Sonus

ABT will return U.S. marketing rights to SNUS's EchoGen perflenapent injectable ultrasound contrast agent. ABT will continue to be responsible for manufacturing until mid-2002. SNUS was down $0.063 to...